SPYRE THERAPEUTICS, INC. Earnings Per Share, Basic and Diluted
SPYRE THERAPEUTICS, INC. (SYRE) reported Earnings Per Share, Basic and Diluted of -$0.37 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-05
- SPYRE THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.37.
- SPYRE THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.31.
- SPYRE THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.10.
- SPYRE THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.28.
- SPYRE THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2021 was -$1.00.
- SPYRE THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2020 was -$1.52.
- SPYRE THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2019 was -$2.45.
- SPYRE THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2018 was -$2.13.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.37 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | -$1.00 10-K · filed 2022-03-08 | |||
| 2021-09-30 | -$0.31 10-Q · filed 2021-11-04 | -$0.69 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | -$0.10 10-Q · filed 2021-08-05 | -$0.38 10-Q · filed 2021-08-05 | ||
| 2021-03-31 | -$0.28 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$0.35 10-K · filed 2021-03-18 | -$1.52 10-K · filed 2022-03-08 | ||
| 2020-09-30 | -$0.29 10-Q · filed 2021-11-04 | -$1.18 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | -$0.40 10-Q · filed 2021-08-05 | -$0.93 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$0.57 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | -$0.65 10-K · filed 2021-03-18 | -$2.45 10-K · filed 2022-03-08 | ||
| 2019-09-30 | -$0.66 10-K · filed 2021-03-18 | -$1.80 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | -$0.55 10-K · filed 2021-03-18 | -$1.14 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | -$0.59 10-K · filed 2021-03-18 | |||
| 2018-12-31 | -$0.62 10-K · filed 2020-02-24 | -$2.13 10-K · filed 2021-03-18 | ||
| 2018-09-30 | -$0.54 10-K · filed 2020-02-24 | -$1.49 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | -$0.46 10-K · filed 2020-02-24 | -$0.94 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | -$0.49 10-K · filed 2020-02-24 | |||
| 2017-12-31 | -$0.39 10-K · filed 2019-03-07 | -$1.80 10-K · filed 2020-02-24 | ||
| 2017-09-30 | -$0.48 10-K · filed 2019-03-07 | -$1.42 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | -$0.47 10-K · filed 2019-03-07 | -$0.94 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | -$0.47 10-K · filed 2019-03-07 | |||
| 2016-12-31 | -$0.41 10-K · filed 2018-03-13 | -$0.88 derived: net income ÷ weighted average shares · filed 2019-03-07 | -$1.34 derived: net income ÷ weighted average shares · filed 2019-03-07 | -$2.22 10-K · filed 2019-03-07 |
| 2016-09-30 | -$0.47 10-K · filed 2018-03-13 | -$0.93 derived: net income ÷ weighted average shares · filed 2017-11-07 | -$1.89 10-Q · filed 2017-11-07 | -$3.06 derived: net income ÷ weighted average shares · filed 2018-03-13 |
| 2016-06-30 | -$0.46 10-K · filed 2018-03-13 | -$1.61 10-Q · filed 2017-08-09 | -$3.21 derived: net income ÷ weighted average shares · filed 2018-03-13 | -$5.09 derived: net income ÷ weighted average shares · filed 2018-03-13 |
| 2016-03-31 | -$7.10 10-K · filed 2018-03-13 | -$13.47 derived: net income ÷ weighted average shares · filed 2018-03-13 | -$19.06 derived: net income ÷ weighted average shares · filed 2018-03-13 | -$21.69 derived: net income ÷ weighted average shares · filed 2018-03-13 |
| 2015-12-31 | -$6.36 10-K · filed 2017-03-23 | -$11.94 derived: net income ÷ weighted average shares · filed 2018-03-13 | -$14.51 derived: net income ÷ weighted average shares · filed 2018-03-13 | -$19.21 10-K · filed 2018-03-13 |
| 2015-09-30 | -$5.57 10-K · filed 2017-03-23 | -$8.08 derived: net income ÷ weighted average shares · filed 2016-11-09 | -$12.76 10-Q · filed 2016-11-09 | |
| 2015-06-30 | -$2.44 10-K · filed 2017-03-23 | -$7.12 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | -$4.71 10-K · filed 2017-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |